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Clinical and genetic characterization of
leukoencephalopathies in adults
David S. Lynch,1,2 Anderson Rodrigues Branda˜o de Paiva,3 Wei Jia Zhang,1
Enrico Bugiardini,4 Fernando Freua,3 Leandro Tavares Lucato,5 Lucia Ineˆs Macedo-Souza,6
Rahul Lakshmanan,7 Justin A. Kinsella,8 Aine Merwick,9,10 Alexander M. Rossor,4,11
Nin Bajaj,12 Brian Herron,13 Paul McMonagle,14 Patrick J. Morrison,15 Deborah Hughes,1
Alan Pittman,1 Matilde Laura`,4 Mary M Reilly,4 Jason D Warren,16 Catherine J Mummery,16
Jonathan M. Schott,16 Matthew Adams,7 Nick C. Fox,16 Elaine Murphy,9
Indran Davagnanam,7 Fernando Kok,3 Jeremy Chataway17 and Henry Houlden1,18
Leukodystrophies and genetic leukoencephalopathies are a rare group of disorders leading to progressive degeneration of cerebral
white matter. They are associated with a spectrum of clinical phenotypes dominated by dementia, psychiatric changes, movement
disorders and upper motor neuron signs. Mutations in at least 60 genes can lead to leukoencephalopathy with often overlapping
clinical and radiological presentations. For these reasons, patients with genetic leukoencephalopathies often endure a long diag-
nostic odyssey before receiving a deﬁnitive diagnosis or may receive no diagnosis at all. In this study, we used focused and whole
exome sequencing to evaluate a cohort of undiagnosed adult patients referred to a specialist leukoencephalopathy service. In total,
100 patients were evaluated using focused exome sequencing of 6100 genes. We detected pathogenic or likely pathogenic variants
in 26 cases. The most frequently mutated genes were NOTCH3, EIF2B5, AARS2 and CSF1R. We then carried out whole exome
sequencing on the remaining negative cases including four family trios, but could not identify any further potentially disease-
causing mutations, conﬁrming the equivalence of focused and whole exome sequencing in the diagnosis of genetic leukoencepha-
lopathies. Here we provide an overview of the clinical and genetic features of these disorders in adults.
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Introduction
Leukodystrophies and genetic leukoencephalopathies repre-
sent a diverse group of disorders in which there is progres-
sive degeneration of CNS white matter. They can present in
children or adults, often with a constellation of clinical
features including dementia, movement disorders, ataxia
and upper motor neuron signs, accompanied by hyperin-
tense signal abnormalities in the brain/spinal cord on T2-
weighted MRI (Vanderver et al., 2015).
There are at least 60 genes implicated in the development
of these disorders, involved in diverse cellular pathways
including myelin formation, mitochondrial health and pro-
tein translation (Parikh et al., 2015). This heterogeneity, in
combination with often overlapping clinical and radio-
logical phenotypes, make deﬁnitive diagnosis challenging.
In addition, the large number of genes and pathways
involved means that the traditional approach to diagnosis,
involving extensive metabolic and biochemical testing, is
time consuming, costly, and often fails to reach a diagnosis
(Richards et al., 2015a).
In recent years, advances have been made in the under-
standing of leukodystrophy and leukoencephalopathy in
children, with particular emphasis on improvements in
diagnostic approach (Vanderver et al., 2016). However,
little is known about the genetic spectrum of these dis-
orders in adults, where in many cases a deﬁnitive diagnosis
is not reached.
In this study, we used focused and whole exome sequen-
cing (WES) to genetically evaluate a cohort of 100 adult
patients with undiagnosed leukodystrophy/leukoencephalo-
pathy, describe the clinical spectrum of these disorders in
adults and explore the efﬁciency of next generation sequen-
cing in their diagnosis.
Materials and methods
Patient recruitment
Patients were recruited from the Queen Square Adult
Leukodystrophy Group (QSALG), a multidisciplinary expert
group that accepts referrals on patients with undiagnosed leu-
kodystrophy/leukoencephalopathy, the Dementia Research
Centre and Neurogenetics Departments of the National
Hospital for Neurology and Neurosurgery, London and the
Neurology Department of the University of Sa˜o Paulo,
Brazil. The primary inclusion criteria included the presence
of a progressive neurological syndrome with prominent T2-
weighted hyperintensity of the cerebral/spinal cord white
matter, which was conﬂuent and not consistent with an
acquired inﬂammatory cause such as multiple sclerosis.
Haematological, biochemical and metabolic testing was per-
formed by the referring centre according to published guide-
lines (Ahmed et al., 2014). All patients underwent Round 1
investigations to exclude acquired causes such as infections or
autoimmune syndromes, and Round 2 investigations to ex-
clude the classical leukodystrophies (white cell enzyme studies,
very long chain fatty acids, amino/organic acids and bile alco-
hols). Some patients also underwent additional muscle/nerve or
brain biopsy. Patients were only included if a diagnosis could
not be reached after these investigations. Informed consent was
obtained from all study participants for genetic analysis and
the study was carried out with institutional ethical approval.
All patients were at least 16 years old at the time of referral to
our centres.
Focused exome and whole exome
sequencing
Genomic DNA was extracted from peripheral blood lympho-
cytes. Focused exome sequencing was performed using the
Agilent Sure Select Focused Exome (Agilent) according to the
manufacturer’s protocol. WES was performed using Nextera
chemistry (Illumina Inc). Sequencing was performed using the
HiSeq platform (Illumina).
The Illumina fastq sequencing data were mapped to the
human reference assembly, hg19 (GRCh37; UCSC genome
browser) by Novoalign Software (Novocraft Inc). After re-
moval of PCR duplicates (Picard) and reads without a
unique mapping location, variants were extracted using the
Maq model in SAMtools and outputted by the following cri-
teria: consensus quality430, SNP quality4 30 and root
mean square mapping quality430. These variant calls were
then annotated using Annovar software (Wang et al., 2010).
Variant prioritization
We initially prioritized variants in known leukodystrophy/gen-
etic leukoencephalopathy genes as recommended by the GLIA
consortium in 2015 (Parikh et al., 2015). We removed syn-
onymous/intronic variants and variants with minor allele fre-
quency (MAF)40.01 on the ExAC database.
Potentially pathogenic variants were conﬁrmed using con-
ventional Sanger sequencing and all variants were classiﬁed
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using American College of Medical Genetics (ACMG) criteria
(Richards et al., 2015b).
Results
Focused exome sequencing identiﬁed pathogenic or likely
pathogenic variants in known leukodystrophy/leukoence-
phalopathy genes in 26 cases (Table 1). The most fre-
quently mutated genes were EIF2B4/5 causing vanishing
white matter (VWM), CSF1R, causing adult onset leukoen-
cephalopathy with axonal spheroids and pigmented glia
(ALSP), AARS2, causing a leukoencephalopathy with ovar-
ian failure and NOTCH3, causing cerebral autosomal
dominant arteriopathy with subcortical infarcts and leu-
koencephalopathy (CADASIL) (Fig. 1). We detected vari-
ants of uncertain signiﬁcance in POLR3A, MRPS22 and
TNR in three patients (Supplementary material).
To assess the utility of focused exome sequencing com-
pared to WES we sequenced the remaining 71 negative
cases (including four family trios) using WES. However,
we did not make any further diagnoses from this approach,
conﬁrming that in adult leukoencephalopathies, WES offers
no beneﬁt over focused exome sequencing. This is likely
because the target coverage is better on focused exome
compared to WES. In our study, coverage metrics showed
that focused exome had mean target coverage of 140 with
99% of targeted bases read4 10 times, compared to WES
where mean targeted coverage was 66 with 94% of tar-
geted bases read410 times (Fig. 1).
It was not possible to predict prospectively which cases
were likely to be positive for a known disease gene. While
negative cases had a slightly older age of onset (mean 35
years) compared to positive cases (mean 32 years), this was
not statistically different (unpaired t-test P-value 0.50).
Similarly, while more positive cases had a family history
(positive cases 42%, negative cases 24%), this was also
not statistically signiﬁcant (Fisher’s exact test P-value
0.10). There was no difference in typical clinical features
or MRI appearance between the two groups
(Supplementary Table 1).
Disease spectrum
Vanishing white matter
We identiﬁed ﬁve patients with VWM disease, four with
mutations in EIF2B5 and one with mutations in EIF2B4.
The average age of onset of neurological symptoms was 36
years. The most frequent symptoms reported were cognitive
decline, ataxia and epilepsy. Of the three female cases, two
experienced premature ovarian failure, with the remaining
female case undergoing menopause at age 45 years. One
patient (Patient P7) presented with trigeminal neuralgia
aged 52 years, and was initially diagnosed with multiple
sclerosis following an abnormal MRI scan. Ten years later,
she developed partial epilepsy and cognitive decline and a
repeat MRI showed ﬁndings typical of VWM. In all cases,
MRI demonstrated bilateral conﬂuent T2-weighted/FLAIR
(ﬂuid-attenuated inversion recovery) hyperintensities with
white matter rarefaction and global atrophy.
CADASIL
We identiﬁed four patients with mutations in the NOTCH3
gene. The average age at onset for these patients was 35
years. Ischaemic stroke and migraine with aura were the
most common symptoms, occurring in three of four pa-
tients. One patient (Patient P4) presented with a prepontine
subarachnoid haemorrhage. Cognitive decline was mild in
all cases. One patient (Patient P4) had no progression 5
years from symptom onset; the remaining three patients
had mild cognitive impairment only after 10 years of
follow-up. The NOTCH3 cases were the only patients to
demonstrate T2-weighted/FLAIR hyperintensity in the tem-
poral poles (Fig. 2A), although this was not universal, with
Patient P1 not showing temporal pole abnormalities on
imaging taken more than 10 years after symptom onset.
CARASAL
We identiﬁed a single patient with the recently described
syndrome of cathepsin A-related arteriopathy with strokes
and leukoencephalopathy (CARASAL) (Bugiani et al.,
2016). The patient had a history of migraine since age 20
in addition to hypertension and depression. She developed
persistent facial pain at age 42 years, which was accompa-
nied by very mild cognitive symptoms consisting of prob-
lems with episodic memory and facial recognition. By age
48, the syndrome had progressed and the patient developed
mild behavioural changes with some disinhibition. Mini-
Mental State Examination was 27/30 and performance IQ
was 99. The neurological examination was normal. The
patient’s father had died from stroke at age 60 years but
no other family members were known to be affected. MRI
demonstrated extensive signal abnormality in the deep and
periventricular white matter sparing the U-ﬁbres, extending
into the thalamus, basal ganglia, pyramidal and tegmental
tracts, the superior and middle cerebellar peduncles and the
right dentate nucleus. A few old lacunes were demonstrated
in the deep grey matter nuclei, although no acute infarcts
or microhaemorrhages were present (Fig. 2B). Both the his-
tory and imaging appearance strongly suggested CADASIL,
but no NOTCH3 mutation was identiﬁed. The same het-
erozygous CTSA mutation, c.973C4T, p.R325C,
described in two families by Bugiani et al. (2016) was de-
tected by focused exome sequencing, conﬁrming the diag-
nosis of the novel entity CARASAL.
CSF1R
We identiﬁed four patients with mutations in CSF1R,
which causes ALSP (Rademakers et al., 2011). Mean age
of onset was 47 years. Two patients (Patients P22 and
P27) presented with cognitive decline and psychiatric
symptoms followed later by upper limb dyspraxia, alien
limb phenomenon and parkinsonism. Patients P20 and
P21 presented with ataxia and spasticity, and later
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developed cognitive decline. In all cases, there was signiﬁ-
cant cognitive decline within 2 years of onset. MRI in all
cases demonstrated slightly asymmetric T2 hyperintense
signal abnormality in the cerebral white matter affecting
the frontal, parietal and temporal lobes with frequent
involvement of the corticospinal tracts and atrophy of
the cerebral white matter and corpus callosum. Punctate
areas of restricted diffusion were also evident in the cere-
bral white matter, which persisted and sometimes
increased over time.
Figure 2 CADASIL and CARASAL imaging appearance. (A) Typical imaging appearance of CADASIL in axial FLAIR MRI images. There is
symmetric subcortical high signal in the anterior temporal lobes, internal and external capsules and scattered asymmetric involvement of the
periventricular cerebral white matter and pons. (B) CARASAL in T2 axial images. There was no involvement of the anterior temporal lobes (left)
but there was extensive involvement of the internal and external capsules, the basal ganglia and thalami (middle) and the periventricular and deep
white matter (right).
Figure 1 Pathogenic and likely pathogenic variants identified in known leukodystrophy/genetic leukoencephalopathy genes
and coverage metrics for focused exome and WES.
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AARS2
Five patients were identiﬁed with biallelic mutations in
AARS2, which has recently been associated with a novel
ovario-leukodystrophy (Dallabona et al., 2014). The clin-
ical details and mutations detected are reported in more
detail elsewhere (Lynch et al., 2016). Brieﬂy, the phenotype
consisted of adult onset leukoencephalopathy with a
variable combination of dementia, upper motor neuron
signs, ataxia and ovarian failure in females. MRI revealed
slightly asymmetric abnormal T2 hyperintense signal in the
frontoparietal and periventricular white matter, with white
matter rarefaction, involvement of the corpus callosum and
pyramidal tracts and punctate areas of restricted diffusion,
reminiscent of ALSP (Fig. 3A). In one case for which brain
Figure 3 AARS2, DARS2 and RNF216 imaging appearance. (A) Typical imaging appearance of AARS2-related leukoencephalopathy. There
is an extensive, symmetric white matter abnormality in the frontal, parietal and occipital lobes on the FLAIR imaging (left), with evidence of
restricted diffusion on diffusion weighted imaging (middle) and apparent diffusion coefficient (right). (B) DARS2-related leukoencephalopathy. Axial
FLAIR MRI image (top left) discloses bilateral deep and periventricular cerebral white matter involvement. Axial and sagittal T2-weighted MRI
images show hyperintensity in the medullary pyramids (red arrows), the posterior columns of the spinal cord (white arrow), the deep white
matter of the cerebellum and along the intraparenchymal tracts of the trigeminal nerves bilaterally (blue arrows), in addition to a lactate peak on
short echo time magnetic resonance spectroscopy (yellow arrow). (C) RNF216-related leukoencephalopathy with diffuse supratentorial white
matter signal abnormality appreciated in axial FLAIR MRI images.
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tissue was available, frequent axonal spheroids and pig-
mented microglia were seen.
Hypomyelinating disorders
We identiﬁed three patients with mutations in genes caus-
ing hypomyelination. Two patients were found to carry
loss-of-function mutations in PLP1. Both patients de-
veloped symptoms at age 30 years. A female patient
(Patient P9), carrying a novel nonsense mutation, presented
with progressive spastic paraplegia and gait ataxia, fol-
lowed by executive dysfunction and impaired visual
memory. It has been shown that symptoms manifest more
commonly in female patients carrying nonsense mutations
in PLP1 (Hurst et al., 2006). A male patient (Patient P10),
carrying a novel frameshift mutation, presented with a ‘no-
no’ head tremor, gait disturbance and bowel and bladder
symptoms at age 30 years. On examination at age 40 years,
there was severe cognitive impairment with frontal release
signs, severe spastic paraparesis requiring wheelchair use,
ideomotor apraxia and near constant head tremor. Both
patients demonstrated mildly increased cerebral white
matter signal on T2-weighted/FLAIR imaging, with the
white matter appearing isointense on T1-weighted images,
indicating hypomyelination.
We identiﬁed a novel de novo mutation in TUBB4A in a
24-year-old female with a childhood onset dystonic syn-
drome with severe lower limb spasticity, dysarthria, cogni-
tive decline and epilepsy (Patient P12). MRI revealed
extensive T2-weighted hyperintensity of the periventricular
and cerebellar white matter extending to the posterior limb
of the internal capsules. The white matter appeared normal
on T1-weighted imaging. The basal ganglia and cerebellum
were not visibly involved by age 24 years.
DARS2
We detected two patients with novel compound heterozy-
gous mutations in DARS2, the mitochondrial aminoacyl
tRNA synthetase for aspartic acid. Recessive mutations in
this gene are associated with the disorder leukoencephalo-
pathy with brainstem and spinal cord involvement and lac-
tate elevation (LBSL) (Scheper et al., 2007). Patient P17
presented at age 8 years with exercise-induced calf cramps.
By age 16, he had developed distal weakness and wasting
with impaired deep tendon reﬂexes and pes cavus. By age 23
there was bilateral extensor plantars and he was diagnosed
with hereditary spastic paraplegia with distal amyotrophy.
The patient continued to decline and by his 40s had de-
veloped a moderate gait ataxia with severe distal weakness
and sensory neuropathy. MRI revealed T2 hyperintense
signal abnormality in the cerebral white matter, splenium
of the corpus callosum, medullary pyramids, medial lem-
nisci, intraparenchymal trigeminal nerves, superior, middle
and inferior cerebellar peduncles, cerebellar white matter
and dorsal columns and lateral corticospinal tracts in the
spinal cord. A lactate peak was detected on intermediate
and long echo time magnetic resonance spectroscopy.
These ﬁndings met the radiological criteria for diagnosis of
LBSL, and the diagnosis was conﬁrmed by the detection of
the compound heterozygous DARS2 variants. Patient P18
developed upper limb intention tremor and slowly progres-
sive gait impairment at age 5. There was slow progression
and gradual development of a sensory ataxia. By age 25 she
had spastic paraplegia with reduced verbal ﬂuency and mild
cognitive impairment. The MRI was consistent with LBSL
and this was conﬁrmed by the presence of compound het-
erozygous DARS2 mutations (Fig. 3B).
RNF216
We identiﬁed a novel homozygous nonsense mutation in
RNF216 in a 42-year-old male with slowly progressive cog-
nitive decline, gait impairment and erectile dysfunction,
starting at age 31 years. A brother was also affected,
with a more rapid progression and death at age 38 years.
On examination, there was evidence of mild cognitive im-
pairment (MMSE 25/30), mild cerebellar ataxia and
choreic movements of the hands and face. MRI demon-
strated a symmetrical and diffuse supra and infra-tentorial
leukoencephalopathy with involvement of the thalamus, ex-
ternal capsules, pons, middle cerebellar peduncles and den-
tate nucleus (Fig. 3C).
Discussion
We used focused exome sequencing as an approach to diag-
nosis in a heterogeneous group of unsolved adult leukody-
strophies/genetic leukoencephalopathies. All of the patients
in our cohort had previously been extensively investigated
without diagnosis. In a cohort of 100 patients, we made a
deﬁnitive diagnosis in 26. This diagnostic rate compares fa-
vourably to other studies using a similar approach. In par-
ticular, Vanderver et al. (2016) made a diagnosis in 25 cases
from 71 families, all of whom were childhood onset cases
with full family trios. In general, diagnostic rates in adult
onset genetic disorders tend to be lower than in children.
This is because the population is more heterogeneous, often
containing some patients with acquired disorders such as
severe small vessel disease and because familial DNA is
not often available in adult onset cases.
In some leukodystrophy/genetic leukoencephalopathy syn-
dromes there is a close phenotype–genotype relationship
allowing for accurate pre-test prediction. For example, the
presence of ataxia and hypogonadotrophic hypogonadism
with leukoencephalopathy strongly suggests Gordon
Holmes syndrome due to RNF216 mutations. Similarly, par-
ticular MRI patterns might signiﬁcantly reduce the number
of genes to screen, such as when hypomyelination is the
predominant feature or the speciﬁc and striking features of
LBSL. However, there remain a large number of patients
who all present in a similar way with a subacute dementing
illness with pyramidal and extrapyramidal features and a
symmetric, non-speciﬁc white matter abnormality. In these
cases, extensive biochemical or metabolic testing is less likely
to be helpful after initial screening is performed (Ahmed
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et al., 2014). Without speciﬁc pretest probability, sequential
candidate gene sequencing is time-consuming, expensive and
can signiﬁcantly delay diagnosis. By contrast focused exome
sequencing is an efﬁcient approach to diagnosis as it simul-
taneously covers all known genes causing leukodystrophies/
genetic leukoencephalopathies.
The number of new genes implicated in genetic leukoen-
cephalopathies is growing each year. This provides chal-
lenges for the use of targeted panels, which inevitably
become obsolete when a number of new genes are
described. Using a focused exome approach offsets this,
as the data can be reanalysed intermittently in light of
new genetic discoveries and compares favourably with
regard to coverage when compared to WES.
In summary, focused exome sequence performs as well as
WES in the diagnosis of adult onset leukodystrophies, pro-
viding a deﬁnite genetic diagnosis in 26%, and revealing
variants of uncertain signiﬁcance in 3%. The 71 negative
cases in our cohort continue to present a diagnostic chal-
lenge. Some of these may not have a Mendelian monogenic
disorders, being either acquired, or due to the interaction of
numerous genetic variants in a polygenic fashion. Some
patients may carry pathogenic intronic variants in known
genes or other mutations not readily detected by NGS
including heterozygous copy number variants. Finally,
some patients will carry pathogenic variants in genes not
yet linked to leukodystrophies/genetic leukoencephalopa-
thies. Further whole exome/genome sequencing along with
family segregation and functional studies may in future re-
solve some, if not all, of these cases.
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